EA201892803A1 - Противоопухолевая терапия - Google Patents

Противоопухолевая терапия

Info

Publication number
EA201892803A1
EA201892803A1 EA201892803A EA201892803A EA201892803A1 EA 201892803 A1 EA201892803 A1 EA 201892803A1 EA 201892803 A EA201892803 A EA 201892803A EA 201892803 A EA201892803 A EA 201892803A EA 201892803 A1 EA201892803 A1 EA 201892803A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protide
methods
cancer
medical applications
derived
Prior art date
Application number
EA201892803A
Other languages
English (en)
Other versions
EA038030B1 (ru
Inventor
Хью Гриффит
Крис Пеппер
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201892803A1 publication Critical patent/EA201892803A1/ru
Publication of EA038030B1 publication Critical patent/EA038030B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Предложены медицинские применения и способы для направленного действия на раковые стволовые клетки с применением соединений ProTide, в частности, для профилактики и лечения рака. Соединение ProTide может отличаться от соединения, выбранного из группы, состоящей из NUC-1031; ProTide, полученного из кордицепина; и ProTide, полученного из 8-хлораденозина. Медицинские применения и способы для направленного действия на раковые стволовые клетки особенно полезны для лечения рецидивирующего или рефрактерного рака у пациентов-людей. В изобретении также предложены способы выбора пациентов, которые будут получать пользу от профилактики или лечения рака посредством медицинских применений или способов лечения согласно изобретению.
EA201892803A 2016-06-01 2017-05-31 Противоопухолевая терапия EA038030B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments
PCT/GB2017/051560 WO2017207993A1 (en) 2016-06-01 2017-05-31 Cancer treatments

Publications (2)

Publication Number Publication Date
EA201892803A1 true EA201892803A1 (ru) 2019-06-28
EA038030B1 EA038030B1 (ru) 2021-06-25

Family

ID=56410849

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892803A EA038030B1 (ru) 2016-06-01 2017-05-31 Противоопухолевая терапия

Country Status (19)

Country Link
US (2) US11400107B2 (ru)
EP (1) EP3463384A1 (ru)
JP (2) JP7367910B2 (ru)
KR (2) KR20220142538A (ru)
CN (1) CN109562119A (ru)
AU (1) AU2017273124B2 (ru)
BR (1) BR112018074981A2 (ru)
CA (1) CA3025442C (ru)
CL (2) CL2018003443A1 (ru)
EA (1) EA038030B1 (ru)
GB (1) GB201609600D0 (ru)
IL (1) IL263123B (ru)
MA (1) MA45129A (ru)
MX (1) MX2018014840A (ru)
MY (1) MY199129A (ru)
PH (1) PH12018502491A1 (ru)
SG (1) SG11201810196RA (ru)
WO (1) WO2017207993A1 (ru)
ZA (1) ZA201807811B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62721B1 (sr) 2011-03-01 2022-01-31 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2’-deoksiuridina za upotrebu u lečenju kancera
EA031727B1 (ru) 2014-11-28 2019-02-28 Нукана Байомед Лимитед Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
AU2019360210A1 (en) * 2018-10-17 2021-06-10 Xibin Liao 6-Mercaptopurine nucleoside analogues
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CA2723648A1 (en) 2008-04-10 2009-10-15 Piyush Gupta Methods for identification and use of agents targeting cancer stem cells
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
RS62721B1 (sr) 2011-03-01 2022-01-31 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2’-deoksiuridina za upotrebu u lečenju kancera
JP2017516779A (ja) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
MY186584A (en) * 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
EA034890B1 (ru) * 2014-06-25 2020-04-02 НУКАНА ПиЭлСи Продукты гемцитабина
EA031727B1 (ru) * 2014-11-28 2019-02-28 Нукана Байомед Лимитед Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
MX2020009154A (es) * 2015-05-14 2022-03-08 NuCana plc Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
AU2017273124B2 (en) 2022-09-29
US20190374564A1 (en) 2019-12-12
CL2018003443A1 (es) 2019-08-09
SG11201810196RA (en) 2018-12-28
AU2017273124A1 (en) 2018-12-13
JP2022051965A (ja) 2022-04-01
MX2018014840A (es) 2019-03-14
CA3025442A1 (en) 2017-12-07
KR20220142538A (ko) 2022-10-21
JP2019521971A (ja) 2019-08-08
WO2017207993A1 (en) 2017-12-07
EP3463384A1 (en) 2019-04-10
CA3025442C (en) 2024-02-20
US11400107B2 (en) 2022-08-02
CN109562119A (zh) 2019-04-02
MA45129A (fr) 2021-05-05
IL263123B (en) 2022-09-01
ZA201807811B (en) 2024-05-30
GB201609600D0 (en) 2016-07-13
EA038030B1 (ru) 2021-06-25
IL263123A (en) 2018-12-31
MY199129A (en) 2023-10-17
BR112018074981A2 (pt) 2019-03-12
PH12018502491A1 (en) 2019-09-09
JP7367910B2 (ja) 2023-10-24
KR20190011770A (ko) 2019-02-07
CL2021002669A1 (es) 2022-05-27
US20230218655A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
EA201892803A1 (ru) Противоопухолевая терапия
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
WO2019226514A3 (en) Molecular gene signatures and methods of using same
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2016070051A3 (en) Combination therapy for treatment of disease
PH12017502086A1 (en) Cancer treatments
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201692472A1 (ru) Соединения для лечения рака мозга
WO2017040666A3 (en) Combination therapy for treatment of disease
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
PH12018502297A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
ZA202202363B (en) Antibodies against ilt2 and use thereof
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2021007484A (es) Compuestos nuevos y su uso en terapia.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021003262A (es) Metodos de tratamiento.
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.